Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People with advanced or metastatic solid tumours (confirmed by tissue testing) whose cancer has continued to grow after standard treatments, who could not tolerate standard treatments, or for whom no standard treatment exists
- People with B-cell lymphoma (confirmed by tissue testing) who have received at least one standard treatment and whose cancer came back or did not respond to that treatment
- People who have measurable or assessable areas of cancer that can be tracked during the trial, as assessed using standard imaging criteria
- People with a good general level of physical functioning, rated 0 or 1 on the ECOG scale (confirm with trial site for exact definition)
- People whose life expectancy is estimated by their doctor to be at least 12 weeks
- People whose liver, kidneys, and other organs are functioning well enough, as determined by medical tests
- People who are able to sign a consent form and follow the study requirements
- Women who could become pregnant, and men, who agree to use effective contraception during treatment and for 90 days after the last dose of the study drug
Who may not be able to join:
- People who have previously been treated with drugs that target QPCTL, CD47, or SIRPα (specific types of cancer-related proteins) (confirm with trial site)
- People diagnosed with Burkitt lymphoma/leukemia, plasma cell myeloma, or plasmablastic lymphoma
- People who have taken part in another therapeutic clinical trial within 28 days (or within 5 half-lives of that treatment, whichever is sooner) before starting this study
- People who have received anti-cancer treatments — such as chemotherapy, immunotherapy, targeted therapy, or biological therapy — within 28 days (or 5 half-lives, whichever is sooner) before starting this study
- People who have had a stem cell transplant (either from a donor or using their own cells) within the 3 months before starting this study
- People who still have unresolved side effects rated above Grade 1 from previous cancer treatments (hair loss is an exception)
- People who have received steroid-based anti-cancer therapy within 7 days before starting this study
- People with a serious illness or significant medical condition (confirm with trial site for full details)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 021-50831718
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose-limiting toxicity (DLT) events; Incidence and severity of adverse events (AEs); Recommended phase 2 dose (RP2D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.